Diabetes Research: Open Access
Hiroshi Bando1,2,3iD*, Hiroko Ogawa3, Masahiro Bando1
1Shikoku Division of Integrative Medicine Japan (IMJ), Tokushima, Japan
2Medical Research/Tokushima University, Tokushima, Japan
3Shuseikai Medical Corporation, Yoshinogawa Hospital, Tokushima, Japan
Corresponding Author: Hiroshi Bando ORCID iD
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 04 April 2024; Accepted date: 11 May 2024; Published date: 18 May 2024
Citation: Bando H, Ogawa H, Bando M. Latest Pharmaceutical Development of Imeglimin Electrospinning Nanofibers for Diabetic Treatment. Diab Res Open Access. 2024 May 18;5(1):05-08.
Copyright © 2024 Bando H, Ogawa H, Bando M. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Keywords: Gastrointestinal Adverse Effect, Imeglimin Electrospinning Nanofibers, Drug Delivery System, Solid Nanofibers Disintegration, Imeglimin, Twymeeg
Abbreviations: GIAE: Gastrointestinal Adverse Effect; DDS: Drug Delivery System
Abstract
Among oral hypoglycemic agents (OHAs), imeglimin (Twymeeg) has been evaluated in clinical practice with Trials of Imeglimin for Efficacy and Safety (TIMES) 1-3 international studies. However, its gastrointestinal adverse effect (GIAE) would be an actual problem. Recently, imeglimin electrospinning nanofibers have been reported as a potential buccal antidiabetic therapeutic approach, which shows absorption not via the gastrointestinal (GI) tract. Imeglimin nanofibers have a diameter of 361 ± 54 nm and a drug-loading (DL) of 23.5 ± 0.2 μg/mg of fibers. The solid nanofibers disintegration takes only 2 ± 1 seconds. This novel medicine is expected to lead to optimal therapeutic outcomes with better patient compliance.
